Journal of Gastrointestinal Surgery

, Volume 21, Issue 7, pp 1153–1158 | Cite as

The Impact of Pathologic Complete Response in Patients with Neoadjuvantly Treated Locally Advanced Rectal Cancer—a Large Single-Center Experience

  • A.M. Dinaux
  • R. Amri
  • L.G. Bordeianou
  • T.S. Hong
  • J.Y. Wo
  • L.S. Blaszkowsky
  • J.N. Allen
  • J.E. Murphy
  • H. Kunitake
  • D.L. BergerEmail author
Original Article


Small cohort studies demonstrated better oncologic outcomes for patients with pathologic complete response (PathCR) after neoadjuvant treatment for locally advanced rectal cancer. This study reviews long-term outcomes of a large cohort of clinically stage II/III rectal cancer patients who received neoadjuvant chemoradiation and surgery. This is a retrospective analysis of a single-center cohort, including all clinical stage II/III rectal cancer patients who received neoadjuvant chemoradiation and surgery between 2004 and 2014 (n = 271). Cox regressions were done to assess the influence of PathCR on recurrence-free survival (RFS) and overall survival (OS), adjusting for postoperative chemotherapy, clinical AJCC staging, comorbidity, and age where appropriate. PathCR patients had significantly lower distant recurrence rates (4 vs. 15.8%; P = 0.028) and lower disease-specific mortality rates (0 vs. 8.1%; P = 0.052), compared to patients with residual disease. PathCR was associated with longer RFS (HR, 5.6 [95% CI 1.3–23.1] P = 0.018) and longer OS (HR, 3.4 [1.31–10.0] P = 0.014) compared to having pathological residual disease. This large single-center study shows that patients with PathCR have significant longer RFS and OS than patients with residual disease on pathology after neoadjuvant chemoradiation.


Rectal cancer Rectal surgery Neoadjuvant therapy Chemoradiation Pathologic complete response 


Authors’ Contribution

All authors contributed substantially to the conception or design of the work or the acquisition, analysis, or interpretation of the data for this manuscript. Furthermore, all authors drafted or revised the manuscript critically for important intellectual content. All authors approved the final version and are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


  1. 1.
    Cagir B, Trostle DR. NCCN guidelines. Medscape eMedicine. 2013. doi: 10.1053/S1053-4296(03)00050-X.Google Scholar
  2. 2.
    Bosset J-F, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol. 2005;23(24):5620–5627. doi: 10.1200/JCO.2005.02.113.CrossRefPubMedGoogle Scholar
  3. 3.
    Medich D, McGinty J, Parda D, et al. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum. 2001;44(8):1123–1128. doi: 10.1007/BF02234632.CrossRefPubMedGoogle Scholar
  4. 4.
    Habr-Gama A, de Souza PM, Ribeiro U, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41(9):1087–1096. Scholar
  5. 5.
    de Campos-Lobato LF, Stocchi L, da Luz Moreira A, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011;18(6):1590–1598. doi: 10.1245/s10434-010-1506-1.CrossRefPubMedGoogle Scholar
  6. 6.
    Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688–8696. doi: 10.1200/JCO.2005.02.1329.CrossRefPubMedGoogle Scholar
  7. 7.
    Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–844. doi: 10.1016/S1470-2045(10)70172-8.CrossRefPubMedGoogle Scholar
  8. 8.
    Martin ST, Heneghan HM, Winter DC. Systematic review and meta-Analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–928. doi: 10.1002/bjs.8702.CrossRefPubMedGoogle Scholar
  9. 9.
    Dahl O, Horn A, Morild I, et al. Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in Western Norway. Cancer. 1990;66(11):2286–2294. doi: 10.1002/1097-0142(19901201)66:11<2286::AID-CNCR2820661106>3.0.CO;2-T.CrossRefPubMedGoogle Scholar
  10. 10.
    Gérard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg. 1988;208(5):606–614.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. Ann Surg Oncol. 2015:1177–1186. doi: 10.1245/s10434-015-5017-y.
  12. 12.
    Chow OS, Kuk D, Keskin M, et al. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016:4–11. doi: 10.1245/s10434-016-5205-4.
  13. 13.
    Ryan JE, Warrier SK, Lynch AC, Heriot AG. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review. Color Dis. 2015;17(10):849–861. doi: 10.1111/codi.13081.CrossRefGoogle Scholar
  14. 14.
    Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: Results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum. 2009;52(12):1927–1934. doi: 10.1007/DCR.0b013e3181ba14ed.CrossRefPubMedGoogle Scholar
  15. 15.
    Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582–589. doi: 10.1097/SLA.0b013e3181b91e63.PubMedGoogle Scholar
  16. 16.
    Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-Analysis of Published Studies. Ann Surg. 2013;0(0):1–8. doi: 10.1097/SLA.0000000000000368.Google Scholar
  17. 17.
    Lefevre JH, Mineur L, Kotti S, et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled Trial (GRECCAR-6). J Clin Oncol. 2016;34. doi: 10.1200/JCO.2016.67.6049.
  18. 18.
    Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711-7-8. doi: 10.1097/01.sla.0000141194.27992.32.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Maas M, Beets-Tan RGH, Lambregts DMJ, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–4640. doi: 10.1200/JCO.2011.37.7176.CrossRefPubMedGoogle Scholar
  20. 20.
    de Jong EA, ten Berge JCEM, Dwarkasing RS, Rijkers AP, van Eijck CHJ. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a metaanalysis. Surgery. 2015;159(3):1–12. doi: 10.1016/j.surg.2015.10.019.Google Scholar
  21. 21.
    Glynne-Jones R, Wallace M, Livingstone JIL, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justified? Dis Colon Rectum. 2008;51(1):10–19. doi: 10.1007/s10350-007-9080-8.
  22. 22.
    Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–190. doi: 10.1016/S1470-2045(13)70599-0.CrossRefPubMedGoogle Scholar
  23. 23.
    Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25(7):1356–1362. doi: 10.1093/annonc/mdu147.CrossRefPubMedGoogle Scholar
  24. 24.
    Breugom AJ, Van Gijn W, Muller EW, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701. doi: 10.1093/annonc/mdu560.CrossRefPubMedGoogle Scholar
  25. 25.
    Bipat S, Glas AS, Slors FJM, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology. 2004;232(3):773–783. doi: 10.1148/radiol.2323031368.CrossRefPubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2017

Authors and Affiliations

  • A.M. Dinaux
    • 1
  • R. Amri
    • 1
  • L.G. Bordeianou
    • 1
  • T.S. Hong
    • 1
  • J.Y. Wo
    • 1
  • L.S. Blaszkowsky
    • 1
  • J.N. Allen
    • 1
  • J.E. Murphy
    • 1
  • H. Kunitake
    • 1
  • D.L. Berger
    • 1
    • 2
    Email author
  1. 1.Department of General and Gastrointestinal Surgery, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Division of General Surgery & Gastrointestinal SurgeryMassachusetts General HospitalBostonUSA

Personalised recommendations